J. Fridman
Molecular Biology · 2002–2010
A researcher in the Science corpus: 6 papers; trusts 3 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 41 citations into it
- Oncology — 37 citations into it; #1,331 of 1,698 by trust here, #601 by citations
Whom J. Fridman trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Karen H. Vousden
- Scott W. Lowe
- G. Evan
- Bert Vogelstein
- Ricky W. Johnstone
- A. Gudkov
- C. Schmitt
- J. Seoane
Who trusts J. Fridman overall
Papers from J. Fridman's perspective
Ordered by how strongly the researchers J. Fridman trusts endorse each paper. Same corpus, a different order for every researcher.
- Proliferation, cell cycle and apoptosis in cancer (Nature)
- Live or let die: the cell's response to p53 (Nature Reviews. Cancer)
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
- Apoptosis A Link between Cancer Genetics and Chemotherapy (Cell)
- Role for the p53 homologue p73 in E2F-1-induced apoptosis (Nature)
- Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome (Nature)
- p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. (Cell)
- Inactivation of the apoptosis effector Apaf-1 in malignant melanoma (Nature)
- Cellular senescence as a tumor-suppressor mechanism. (Trends in Cell Biology)
- Endonuclease G is an apoptotic DNase when released from mitochondria (Nature)
Their papers
- Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy (2004) — 1,001 citations
- Control of apoptosis by p53 (2003) — 1,468 citations
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. (2010) — 820 citations
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis (2010) — 1,143 citations
- Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer (2007) — 145 citations
- A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. (2002) — 1,074 citations